Trials / Unknown
UnknownNCT05385185
Clinical Observation of ICI Combined With Recombinant Human Endostatin on Leptomeningeal Metastasis of Lung Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Hebei Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
immune checkpoint inhibitor combined with recombinant human endostatin can improve the 3-month OS rate of leptomeningeal metastasis of lung cancer, and the combination is safe
Detailed description
We will recruit 20 patients with leptomeningeal metastases from lung cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Camrelizumab or envafolimab | combine Camrelizumab or envafolimab with Recombinant human vascular endostatin |
Timeline
- Start date
- 2022-05-01
- Primary completion
- 2024-05-03
- Completion
- 2024-12-03
- First posted
- 2022-05-23
- Last updated
- 2022-05-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05385185. Inclusion in this directory is not an endorsement.